- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MacroGenics Inc (MGNX)
The MacroGenics Inc share price today is 3.00, view NASDAQ MGNX stock exchange data. Track the latest MacroGenics Inc share price with real-time updates on MGNX stock performance including market cap, day range, 52-week range and dividend yield. Access MGNX charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.90
3.10
52 wk Range
1.19
3.88
Earnings results expected in 5 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.903.10
52 wk Range
1.193.88
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MGNX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
6.00
Upside
+100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 8K MacroGenics Inc For: 8 April
- Investing.com
- Macrogenics receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Macrogenics receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
4 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 6.00
(+100.00% Upside)
MacroGenics Inc SWOT Analysis
Pipeline Progress | Explore MacroGenics' evolving pipeline, featuring promising candidates like lorigerlimab and MGC026, as the company pivots from discontinued programs to new opportunities |
Financial Fortification | Delve into MacroGenics' strategic moves, including a $70M royalty agreement, extending cash runway to 2027 and bolstering its position for future growth |
Catalysts on Horizon | Uncover critical upcoming events for MacroGenics, including Phase 2 data readouts and potential partnerships, that could significantly impact company valuation |
Market Valuation | Analyst price targets range from $2 to $8 per share, reflecting diverse perspectives on MacroGenics' potential in a competitive biotech landscape |
MacroGenics Inc Earnings Call Summary for Q4/2024
- Q4 2024 EPS of -$0.07 beat expectations of -$0.40; revenue reached $49.4M, surpassing $29.19M forecast
- 2024 total revenue of $150M, up from $58.7M in 2023; net loss increased to $67M due to higher R&D expenses
- Cash balance of $201.7M extends runway into H2 2026; stock rose 4.29% in after-hours trading
- Clinical updates expected in H2 2025, including LORIKET trial data and MGC-26 dose expansion results
- CEO optimistic about 2025 pipeline advancement; CMO highlighted differentiated approach in checkpoint inhibitors
Last Updated: 21-03-2025, 03:00 am
Read Full TranscriptEarnings
Latest Release
09-03-2026
EPS / Forecast
-0.23 / -0.20
Revenue / Forecast
41.23M / 30.49M
Compare MGNX to Peers and Sector
Metrics to compare | MGNX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMGNXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.5x | −2.4x | −0.6x | |
PEG Ratio | 0.24 | 0.11 | 0.00 | |
Price/Book | 3.4x | 1.9x | 2.6x | |
Price / LTM Sales | 1.3x | 8.8x | 3.2x | |
Upside (Analyst Target) | 82.7% | 94.2% | 48.1% | |
Fair Value Upside | Unlock | 6.9% | 5.8% | Unlock |
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the MacroGenics Inc (MGNX) Share Price Today?
The MacroGenics Inc share price today is 3.00.
What is the current MacroGenics Inc (MGNX) share price and day range?
As of 08-05-2026, the MacroGenics Inc share price is 3.00, with a previous close of 2.94. The share price has ranged from 2.90 to 3.10 today, while the 52-week range spans from 1.19 to 3.88.
What Is the MacroGenics Inc Market Cap?
As of today, MacroGenics Inc market cap is 191.32M.
What Is the MacroGenics Inc (MGNX) Share Price Target?
The average 12-month share price target for MacroGenics Inc is 6.00, with a high estimate of 9 and a low estimate of 4. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +100.00% Upside potential.
What Is MacroGenics Inc's Earnings Per Share (TTM)?
The MacroGenics Inc EPS (TTM) is -1.18.
When Is the Next MacroGenics Inc Earnings Date?
MacroGenics Inc will release its next earnings report on 13-05-2026.
From a Technical Analysis Perspective, Is MGNX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does MacroGenics Inc Trade On?
MacroGenics Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for MacroGenics Inc?
The stock symbol for MacroGenics Inc is "MGNX."
How Many Times Has MacroGenics Inc Stock Split?
MacroGenics Inc has split 0 times.
How Many Employees Does MacroGenics Inc Have?
MacroGenics Inc has 293 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.